Business
Appointment of Shaun Furlong to Board of Directors
Appointment of Shaun Furlong to Board of Directors.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n \n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\", the \"Group\" or \"Company\")\n \n \nAppointment of Dr. Shaun Furlong to Board of Directors\n \n11 March 2024 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, is pleased to announce the appointment of Shaun Furlong as an Executive Director of the Company, with effect from 8 March 2024.\n \nShaun was appointed as the Group's Chief Financial Officer (CFO) in August 2023, having previously served as Group Financial Controller since April 2022. He brings significant financial experience, having held senior finance roles within blue-chip companies across multiple sectors, including Legal & General, Hastings Direct, Volution Group and American Express. Shaun is a Fellow of the Institute of Chartered Accountants in England and Wales and holds a PhD in polymer chemistry from the University of Sussex.\n \nPeter Jensen, Chairman of Allergy Therapeutics, commented: \"Shaun has proven himself to be an invaluable asset to the Company since his appointment as Group Financial Controller and more recently since his appointment as Chief Financial Officer last year. Given his professionalism, strong financial acumen and range of experience, I have no doubt that he will be an important contributor to the Board.\"\n \nCommenting on his appointment, Shaun Furlong said: \" I am delighted to take on an expanded leadership role as an Executive Director and look forward to working alongside the other members of the Board.\"\n \nAdditional Information in respect of the AIM Rules:\nShaun Antony Furlong, aged 48, holds an interest in 1,500 ordinary shares in the Company. In the previous five years, Shaun was a director of SAF Management Services Limited. The Company confirms that there is no other information in relation to Shaun's appointment that is required to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.\n \n \nFor further information, please contact:\n \nAllergy Therapeutics\nManuel Llobet, Chief Executive Officer\nShaun Furlong, Chief Financial Officer\n+44 (0)1903 845 820\n \nPanmure Gordon (Nominated Adviser and Broker)\nEmma Earl, Freddy Crossley, Mark Rogers, Corporate Finance\nRupert Dearden, Co...